Nonmyeloablative allogeneic stem cell transplantation from HLA [human leucocyte antigen]-matched unrelated donor for the treatment of hematologic disorders.

Trial Profile

Nonmyeloablative allogeneic stem cell transplantation from HLA [human leucocyte antigen]-matched unrelated donor for the treatment of hematologic disorders.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Sargramostim
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 22 Jun 2011 Planned end date (Jan 2007) added as reported by ClinicalTrials.gov..
    • 01 Dec 2008 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top